MicroRNA-1291 (miR-1291)

MicroRNA-1291 (miR-1291) is a small, non-coding RNA molecule classified as a microRNA, which acts as a regulator of post-transcriptional gene expression by binding to target messenger RNAs and inhibiting their translation or promoting their degradation[1][2]. miR-1291 is located in the human genome at 12q13.11 and is nested in the intron of the KANSL2 gene[2]. It has been shown to play a tumor-suppressive role in several cancers, including pancreatic, renal, and colon cancers, where its expression is often downregulated[1][2][3]. miR-1291 directly or indirectly targets oncogenic and metabolic genes including SLC2A1 (GLUT1), ERRα (ESRRA), and CPT1C, contributing to inhibition of cell proliferation, cell cycle progression, and metabolic reprogramming of tumor cells[1][2]. Additionally, miR-1291 can modulate drug resistance by targeting multidrug resistance-associated genes such as ABCC1/MRP1, thereby increasing sensitivity to chemotherapeutic agents like doxorubicin[1][3]. Beyond oncology, miR-1291 is emerging as a biomarker in cardiovascular, autoimmune, and infectious diseases[3]. The mechanism of miR-1291 action involves multifaceted regulation of cell growth, apoptosis, metabolism, and chemosensitivity, making it a potential target for therapeutic intervention and disease monitoring[1][2][3].

Other names

hsa-miR-1291MIR1291MIRN1291hsa-mir-1291mir-1291

Increases chemosensitivity to antineoplastic agents (e.g., doxorubicin) by downregulation of drug resistance transporters (ABCC1/MRP1). Suppression of oncogenic pathways via direct targeting of metabolic and cell cycle regulators (e.g., ERRα, CPT1C, SLC2A1/GLUT1).